FDCFDC Limited
Pharma · Drug Manufacturers - Specialty & Generic · NSE · as of 2026-10-26 (delayed ~30 min in market hours)
FDC Limited, together with its subsidiaries, manufactures and trades in pharmaceutical products in India, the United States, and internationally. The company offers pharmaceutical formulations for various therapeutic segments, including anti-infectives, gastrointestinal, ophthalmology, vitamins, minerals, dietary supplements, cardiovascular and anti-diabetic therapies, respiratory care, gynaecology, dermatology, and analgesics in the form of tablets, capsules, oral liquids, ophthalmic drops, topical preparations, and paediatric-friendly solutions. It also provides functional food, such as flavoured ORS powders, ready-to-drink electrolyte beverages, vitamin-enriched supplements, antioxidant blends and protein-fortified drinks; and various active pharmaceutical ingredients. The company sells its products under the Zifi, Zefu, Zocon, Amodep-AT, Zathrin, Vitcofol, Ziglim, Ziglim-M,Mycoderm, Zoxan, Cotaryl, Pyrimon DF, Zipod, Electral, and Enerzal brands. It also exports its products to approximately 50 countries. FDC Limited was founded in 1936 and is based in Mumbai, India.
Price & Volume
Loading chart…
Key Ratios
“—” means the figure isn't meaningful or isn't published for this company: ROE and Debt/Equity are undefined when shareholder equity is negative (check P/B — negative means negative equity), and DII/MF holding splits aren't provided by our current data source.
Active Pattern Signals
The picture
- • Revenue growth: 18.9% YoY
- • Profit growth: 166.8% YoY
- • Debt/Equity: 0.01
- • RSI: 52
- • MACD: bullish
- • Price vs EMA21: above
- • Bullish Engulfing signal (setup quality 56%)
Bull case
- • Revenue growth: 18.9% YoY
- • Profit growth: 166.8% YoY
- • Debt/Equity: 0.01
- • RSI: 52
Bear case
- • Price vs SMA200: below
- • Golden cross setup: SMA50 below SMA200
- • 1-month return: +0.2%
- • 3-month return: -15.0%
Key risks
- • Momentum is fading versus the broader market
- • Price vs SMA200: below
- • Golden cross setup: SMA50 below SMA200
Algorithmic analysis for research only — not SEBI-registered investment advice.
Trade Plan
Stop = 20-day support with a 2.5×ATR risk cap (ATR ₹12.27). Levels recompute on every data refresh. Position sizing and execution are yours — this is analysis, not advice.